Loading...
OTC Markets
Totals
Securities
12,306
Dollar Vol
$2.0B
Share Vol
4B
Trades
367,183

OTC Markets Group uses cookies and similar technologies to help us understand how you use our websites, as further disclosed in our Privacy Policy. Our Terms of Service contain important information including restrictions on your use of our websites. By clicking “Accept”, or by continuing to use our websites, you consent to the use of cookies and agree to the terms of the OTC Markets Group Privacy Policy and Terms of Service.

CYDY
CytoDyn Inc.

Common Stock

0.315

-0.0032

-1.01%

0.302 / 0.32 (19041 x 30325)

Real-Time Best Bid & Ask: 05:00pm 07/11/2025
Delayed (15 Min) Trade Data: 12:00am 07/11/2025
OTC Disclosure & News Service

Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until May 17, 2021 to file lead plaintiff applications in a securities class action lawsuit against CytoDyn, Inc. (OTC: CYDY), if they purchased the Company’s securities between March 27, 2020 through March 9, 2021, inclusive (the “Class Period”). This action is pending in the United States District Court for the Western District of Washington.

What You May Do

If you purchased securities of CytoDyn and would like to discuss your legal rights and how this case might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, contact KSF Managing Partner Lewis Kahn toll-free at 1-877-515-1850 or via email (lewis.kahn@ksfcounsel.com), or visit https://www.ksfcounsel.com/cases/otc-cydy/ to learn more. If you wish to serve as a lead plaintiff in this class action, you must petition the Court by May 17, 2021.

About the Lawsuit

CytoDyn and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.

On March 5, 2021, the Company issued a press release purporting to tout the positive trial results of its product Leronlimab, stating in part, that “the Phase 3 trial of leronlimab for the treatment of severe-to-critical patients with COVID-19 demonstrated continued safety, substantial improvement in the survival rate, and faster hospital discharge in critically ill COVID-19 patients”; however, as subsequently highlighted by industry analysts in the following days, the Company also disclosed that “[a]mongst all patients in mITT, the primary endpoint (all-cause mortality at Day 28) was not statistically significant.”

On this news, shares of CytoDyn plummeted.

The case is Lewis v. CytoDyn, Inc., No. 3:21-cv-05190.

About Kahn Swick & Foti, LLC

KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation’s premier boutique securities litigation law firms. KSF serves a variety of clients – including public institutional investors, hedge funds, money managers and retail investors – in seeking to recover investment losses due to corporate fraud and malfeasance by publicly traded companies. KSF has offices in New York, California and Louisiana.

To learn more about KSF, you may visit www.ksfcounsel.com.

OTCQB Venture Market Logo
Joined OTCQB 10/2014
The Company Profile data was verified by the issuer within the previous 6 months.
The company’s transfer agent has verified its outstanding shares directly to OTC Markets.
The Company’s board of directors includes at least two Independent Directors.
Daily Advancers
Subscribe to Our Newsletter
Stay up to date on the latest company news, industry trends and regulatory changes that affect our markets and learn about members of our community.